DAFNA Capital Management LLC Sells 69,000 Shares of CymaBay Therapeutics Inc. (CBAY)
DAFNA Capital Management LLC lowered its position in CymaBay Therapeutics Inc. (NASDAQ:CBAY) by 78.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,067 shares of the biopharmaceutical company’s stock after selling 69,000 shares during the quarter. DAFNA Capital Management LLC owned approximately 0.07% of CymaBay Therapeutics worth $110,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of CBAY. Bank of New York Mellon Corp lifted its stake in CymaBay Therapeutics by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares during the last quarter. ClariVest Asset Management LLC purchased a new position in CymaBay Therapeutics in the first quarter worth approximately $105,000. LVM Capital Management Ltd. MI lifted its stake in CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 10,000 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in CymaBay Therapeutics in the second quarter worth approximately $242,000. Finally, Renaissance Technologies LLC lifted its stake in CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock worth $997,000 after acquiring an additional 114,549 shares during the last quarter. Institutional investors own 25.91% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “DAFNA Capital Management LLC Sells 69,000 Shares of CymaBay Therapeutics Inc. (CBAY)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/dafna-capital-management-llc-sells-69000-shares-of-cymabay-therapeutics-inc-cbay/1612992.html.
In other CymaBay Therapeutics news, insider Sujal Shah bought 10,000 shares of CymaBay Therapeutics stock in a transaction dated Thursday, July 20th. The stock was bought at an average cost of $7.34 per share, for a total transaction of $73,400.00. Following the purchase, the insider now owns 75,891 shares in the company, valued at approximately $557,039.94. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kurt Von Emster sold 211,124 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $8.09, for a total value of $1,707,993.16. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 20,000 shares of company stock valued at $144,750. Company insiders own 15.10% of the company’s stock.
Shares of CymaBay Therapeutics Inc. (CBAY) traded up 1.36% during mid-day trading on Friday, hitting $8.19. 397,969 shares of the stock traded hands. The stock’s market cap is $358.36 million. The stock has a 50-day moving average of $6.94 and a 200 day moving average of $5.47. CymaBay Therapeutics Inc. has a one year low of $1.15 and a one year high of $8.45.
CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.06). Equities analysts predict that CymaBay Therapeutics Inc. will post ($0.82) EPS for the current fiscal year.
A number of research analysts recently issued reports on CBAY shares. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Cantor Fitzgerald started coverage on shares of CymaBay Therapeutics in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 price target for the company. Leerink Swann started coverage on shares of CymaBay Therapeutics in a research note on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 price target for the company. Ifs Securities reiterated a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Finally, Piper Jaffray Companies set a $7.00 price target on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. CymaBay Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.00.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.